Author

Gigi Shafai

Institution: Pear Therapeutics (United States)

Observed institutions: Pear Therapeutics (United States), Catabasis Pharmaceuticals (United States)

ORCID: 0000-0002-7165-0276

Observed ORCID: 0000-0002-7165-0276

OpenAlex ID: A5012461161

FDA regulations and prescription digital therapeutics: Evolving with the technologies they regulate

2023 · Anthony Watson, Richard Chapman, et al. · Frontiers in Digital Health · 59

Evaluation of real‐world outcomes associated with use of a prescription digital therapeutic to treat substance use disorders

2022 · Xiaorui Xiong, Stephen Braun, et al. · American Journal on Addictions · 26

Prescription digital therapeutics: A new frontier for pharmacists and the future of treatment

2023 · Gigi Shafai, Timothy D. Aungst · Journal of the American Pharmacists Association · 15

Assessing the ability of boys with Duchenne muscular dystrophy age 4–7 years to swallow softgel capsules: Clinical trial experience with edasalonexent

2021 · Maria Mancini, Gigi Shafai, et al. · Journal of Clinical Pharmacy and Therapeutics · 2

Engagement patterns and clinical outcomes across primary substance use categories after 12 and 24 weeks of treatment with a prescription digital therapeutic for substance use (Preprint)

2023 · Justin Enggasser, Xiaorui Xiong, et al.

Works count: 5

Citation count: 102

H-index: 3

I10-index: 3